Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival
TL;DR: Results are presented of the largest study demonstrating improved myelofibrosis-free and overall survival (MFS and OS) of rIFNa treated PV patients (pts) compared to other PV pts and the effectiveness of PV therapy using both intention-to-treat (ITT) and treatment duration (on-treatment) analyses.
About: This article is published in Blood.The article was published on 2019-11-13. It has received 4 citations till now.
Citations
More filters
TL;DR: The challenges of addressing data gaps and outstanding questions in the emerging treatment landscape of PV are highlighted, as well as an expanding portfolio of active drugs.
3 citations
TL;DR: In this paper, consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of Thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression.
Abstract: Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification.
1 citations
1 citations